Acorda Third Quarter 2020 Update: Webcast/Conference Call Scheduled for November 3, 2020
October 27 2020 - 7:00AM
Business Wire
Acorda Therapeutics, Inc. (NASDAQ: ACOR) will host a conference
call and webcast in conjunction with its third quarter 2020 update
and financial results on Tuesday, November 3 at 4:30 p.m. ET.
To participate in the Webcast/Conference call, please note there
is a new pre-registration process.
- To register for the Webcast/Conference Call, use the link
below: http://www.directeventreg.com/registration/event/4177747
**When registering please type your phone number with no special
characters**
Once you have registered, you will receive a confirmation email
with Webcast/Conference Call details. For the Webcast you will
receive an email 2 hours prior to the start of the call with the
link to join. The presentation will be available on the Investors
section of www.acorda.com.
A replay of the call will be available from 7:30 p.m. ET on
November 3, 2020 until 11:59 p.m. ET on December 3, 2020. To access
the replay, please dial (800) 585-8367 (domestic) or (416) 621-4642
(international); reference code 4177747. The archived webcast will
be available in the Investor Relations section of the Acorda
website at www.acorda.com.
About Acorda Therapeutics
Acorda Therapeutics develops therapies to restore function and
improve the lives of people with neurological disorders. INBRIJA®
(levodopa inhalation powder) is approved for intermittent treatment
of OFF episodes in adults with Parkinson’s disease treated with
carbidopa/levodopa. INBRIJA is not to be used by patients who take
or have taken a nonselective monoamine oxidase inhibitor such as
phenelzine or tranylcypromine within the last two weeks. INBRIJA
utilizes Acorda’s innovative ARCUS® pulmonary delivery system, a
technology platform designed to deliver medication through
inhalation. Acorda also markets the branded AMPYRA® (dalfampridine)
Extended Release Tablets, 10 mg.
Forward-Looking Statements
This press release includes forward-looking statements. All
statements, other than statements of historical facts, regarding
management's expectations, beliefs, goals, plans or prospects
should be considered forward-looking. These statements are subject
to risks and uncertainties that could cause actual results to
differ materially, including: we may not be able to successfully
market INBRIJA or any other products under development; the
COVID-19 pandemic, including related quarantines and travel
restrictions, and the potential for the illness to affect our
employees or consultants or those that work for other companies we
rely upon, could have a material adverse effect on our business
operations or product sales; our ability to raise additional funds
to finance our operations, repay outstanding indebtedness or
satisfy other obligations, and our ability to control our costs or
reduce planned expenditures and take other actions which are
necessary for us to continue as a going concern; risks associated
with complex, regulated manufacturing processes for
pharmaceuticals, which could affect whether we have sufficient
commercial supply of INBRIJA to meet market demand; third party
payers (including governmental agencies) may not reimburse for the
use of INBRIJA or our other products at acceptable rates or at all
and may impose restrictive prior authorization requirements that
limit or block prescriptions; competition for INBRIJA, AMPYRA and
other products we may develop and market in the future, including
increasing competition and accompanying loss of revenues in the
U.S. from generic versions of AMPYRA (dalfampridine) following our
loss of patent exclusivity; the ability to realize the benefits
anticipated from acquisitions, among other reasons because acquired
development programs are generally subject to all the risks
inherent in the drug development process and our knowledge of the
risks specifically relevant to acquired programs generally improves
over time; the risk of unfavorable results from future studies of
INBRIJA (levodopa inhalation powder) or from our other research and
development programs, or any other acquired or in-licensed programs
; the occurrence of adverse safety events with our products; the
outcome (by judgment or settlement) and costs of legal,
administrative or regulatory proceedings, investigations or
inspections, including, without limitation, collective,
representative or class action litigation; failure to protect our
intellectual property, to defend against the intellectual property
claims of others or to obtain third party intellectual property
licenses needed for the commercialization of our products; and
failure to comply with regulatory requirements could result in
adverse action by regulatory agencies.
These and other risks are described in greater detail in our
filings with the Securities and Exchange Commission. We may not
actually achieve the goals or plans described in our
forward-looking statements, and investors should not place undue
reliance on these statements. Forward-looking statements made in
this press release are made only as of the date hereof, and we
disclaim any intent or obligation to update any forward-looking
statements as a result of developments occurring after the date of
this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201027005087/en/
Tierney Saccavino (917) 783-0251 tsaccavino@acorda.com
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Apr 2023 to Apr 2024